A nationwide analysis on the interaction between frailty and beta-blocker therapy in hip fracture patients.

Maximilian Peter Forssten Ahmad Mohammad IsmailIoannis IoannidisPer WretenbergTomas BorgDhanisha Jayesh Trivedi Marcelo Augusto Fontenelle Ribeiro Junior Shahin Mohseni

Published in: European journal of trauma and emergency surgery : official publication of the European Trauma Society (2023)

Beta-blocker therapy is associated with a reduced risk of 30-day postoperative mortality in frail hip fracture patients, with a greater effect being observed with higher Orthopedic Hip Frailty Scores.

Keyphrases

hip fracture
end stage renal disease
community dwelling
newly diagnosed
ejection fraction
patients undergoing
prognostic factors
stem cells
cardiovascular disease
type diabetes
cardiovascular events
angiotensin converting enzyme
cross sectional
mesenchymal stem cells
patient reported